Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration
Identifieur interne : 003722 ( Main/Exploration ); précédent : 003721; suivant : 003723Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration
Auteurs : Emma C. Schofield [Australie] ; Diana Caine [Australie] ; Jillian J. Kril [Australie] ; Nicholas J. Cordato [Australie] ; Glenda M. Halliday [Australie]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-01.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Atrophy, Basal Ganglia Diseases (metabolism), Basal Ganglia Diseases (pathology), Chi-Square Distribution, Degeneration, Encephalon, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nerve Degeneration (classification), Nerve Degeneration (metabolism), Nerve Degeneration (physiopathology), Nervous system diseases, Prospective Studies, Supranuclear Palsy, Progressive (metabolism), Supranuclear Palsy, Progressive (pathology), atrophy, corticobasal degeneration, progressive supranuclear palsy, staging, tau Proteins (metabolism), tauopathy.
- MESH :
- chemical , metabolism : tau Proteins.
- classification : Nerve Degeneration.
- metabolism : Basal Ganglia Diseases, Nerve Degeneration, Supranuclear Palsy, Progressive.
- pathology : Basal Ganglia Diseases, Supranuclear Palsy, Progressive.
- physiopathology : Nerve Degeneration.
- Aged, Aged, 80 and over, Atrophy, Chi-Square Distribution, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies.
Abstract
The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ2 = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20286
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001D76
- to stream Istex, to step Curation: 001D76
- to stream Istex, to step Checkpoint: 002128
- to stream PubMed, to step Corpus: 003230
- to stream PubMed, to step Curation: 003230
- to stream PubMed, to step Checkpoint: 002F54
- to stream Ncbi, to step Merge: 001058
- to stream Ncbi, to step Curation: 001058
- to stream Ncbi, to step Checkpoint: 001058
- to stream Main, to step Merge: 004E05
- to stream PascalFrancis, to step Corpus: 001F41
- to stream PascalFrancis, to step Curation: 000D80
- to stream PascalFrancis, to step Checkpoint: 001D07
- to stream Main, to step Merge: 005185
- to stream Main, to step Curation: 003722
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title><author><name sortKey="Schofield, Emma C" sort="Schofield, Emma C" uniqKey="Schofield E" first="Emma C." last="Schofield">Emma C. Schofield</name></author><author><name sortKey="Caine, Diana" sort="Caine, Diana" uniqKey="Caine D" first="Diana" last="Caine">Diana Caine</name></author><author><name sortKey="Kril, Jillian J" sort="Kril, Jillian J" uniqKey="Kril J" first="Jillian J." last="Kril">Jillian J. Kril</name></author><author><name sortKey="Cordato, Nicholas J" sort="Cordato, Nicholas J" uniqKey="Cordato N" first="Nicholas J." last="Cordato">Nicholas J. Cordato</name></author><author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9F073D1FCDB3A7E66F3982825948EC8631FD9849</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20286</idno><idno type="url">https://api.istex.fr/document/9F073D1FCDB3A7E66F3982825948EC8631FD9849/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001D76</idno><idno type="wicri:Area/Istex/Curation">001D76</idno><idno type="wicri:Area/Istex/Checkpoint">002128</idno><idno type="wicri:doubleKey">0885-3185:2005:Schofield E:staging:disease:severity</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15390131</idno><idno type="wicri:Area/PubMed/Corpus">003230</idno><idno type="wicri:Area/PubMed/Curation">003230</idno><idno type="wicri:Area/PubMed/Checkpoint">002F54</idno><idno type="wicri:Area/Ncbi/Merge">001058</idno><idno type="wicri:Area/Ncbi/Curation">001058</idno><idno type="wicri:Area/Ncbi/Checkpoint">001058</idno><idno type="wicri:doubleKey">0885-3185:2005:Schofield E:staging:disease:severity</idno><idno type="wicri:Area/Main/Merge">004E05</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0173684</idno><idno type="wicri:Area/PascalFrancis/Corpus">001F41</idno><idno type="wicri:Area/PascalFrancis/Curation">000D80</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001D07</idno><idno type="wicri:doubleKey">0885-3185:2005:Schofield E:staging:disease:severity</idno><idno type="wicri:Area/Main/Merge">005185</idno><idno type="wicri:Area/Main/Curation">003722</idno><idno type="wicri:Area/Main/Exploration">003722</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration</title><author><name sortKey="Schofield, Emma C" sort="Schofield, Emma C" uniqKey="Schofield E" first="Emma C." last="Schofield">Emma C. Schofield</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick</wicri:regionArea><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author><author><name sortKey="Caine, Diana" sort="Caine, Diana" uniqKey="Caine D" first="Diana" last="Caine">Diana Caine</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Psychology, The University of Sydney, Camperdown</wicri:regionArea><wicri:noRegion>Camperdown</wicri:noRegion></affiliation></author><author><name sortKey="Kril, Jillian J" sort="Kril, Jillian J" uniqKey="Kril J" first="Jillian J." last="Kril">Jillian J. Kril</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Centre for Education and Research on Ageing, The University of Sydney, Concord Hospital, Concord</wicri:regionArea><wicri:noRegion>Concord</wicri:noRegion></affiliation></author><author><name sortKey="Cordato, Nicholas J" sort="Cordato, Nicholas J" uniqKey="Cordato N" first="Nicholas J." last="Cordato">Nicholas J. Cordato</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Geriatric Medicine, Westmead Hospital and The University of Sydney, Westmead</wicri:regionArea><wicri:noRegion>Westmead</wicri:noRegion></affiliation></author><author><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Prince of Wales Medical Research Institute and the University of New South Wales, Randwick</wicri:regionArea><wicri:noRegion>Randwick</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-01">2005-01</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="34">34</biblScope><biblScope unit="page" to="39">39</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9F073D1FCDB3A7E66F3982825948EC8631FD9849</idno><idno type="DOI">10.1002/mds.20286</idno><idno type="ArticleID">MDS20286</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Atrophy</term><term>Basal Ganglia Diseases (metabolism)</term><term>Basal Ganglia Diseases (pathology)</term><term>Chi-Square Distribution</term><term>Degeneration</term><term>Encephalon</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nerve Degeneration (classification)</term><term>Nerve Degeneration (metabolism)</term><term>Nerve Degeneration (physiopathology)</term><term>Nervous system diseases</term><term>Prospective Studies</term><term>Supranuclear Palsy, Progressive (metabolism)</term><term>Supranuclear Palsy, Progressive (pathology)</term><term>atrophy</term><term>corticobasal degeneration</term><term>progressive supranuclear palsy</term><term>staging</term><term>tau Proteins (metabolism)</term><term>tauopathy</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>tau Proteins</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Nerve Degeneration</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Nerve Degeneration</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Nerve Degeneration</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Atrophy</term><term>Chi-Square Distribution</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Atrophie</term><term>Dégénérescence</term><term>Encéphale</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Broe et al., Neurology 2003;60:1005–1011] was applied to pathologically confirmed PSP (n = 24) and CBD (n = 9) cases and correlated with clinical indices. In contrast to frontotemporal dementia, the majority of PSP cases had limited or no visible atrophy, while the pattern of atrophy in CBD cases conformed to the existing staging scheme (all but one case exhibiting substantial visible tissue atrophy). Despite similar clinical severity and disease duration between groups, there was a marked difference between the PSP and CBD cases in pathological disease stage (χ2 = 8.86; P = 0.03). The degree of global atrophy in PSP appears to be distinct from other tauopathies, while CBD fits the same pattern as other pathological forms of frontotemporal dementia. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Schofield, Emma C" sort="Schofield, Emma C" uniqKey="Schofield E" first="Emma C." last="Schofield">Emma C. Schofield</name></noRegion><name sortKey="Caine, Diana" sort="Caine, Diana" uniqKey="Caine D" first="Diana" last="Caine">Diana Caine</name><name sortKey="Cordato, Nicholas J" sort="Cordato, Nicholas J" uniqKey="Cordato N" first="Nicholas J." last="Cordato">Nicholas J. Cordato</name><name sortKey="Halliday, Glenda M" sort="Halliday, Glenda M" uniqKey="Halliday G" first="Glenda M." last="Halliday">Glenda M. Halliday</name><name sortKey="Kril, Jillian J" sort="Kril, Jillian J" uniqKey="Kril J" first="Jillian J." last="Kril">Jillian J. Kril</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003722 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003722 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9F073D1FCDB3A7E66F3982825948EC8631FD9849
|texte= Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration
}}
| This area was generated with Dilib version V0.6.23. |  |